Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Artelo Biosciences (Nasdaq: ARTL) has initiated the Phase 2a segment of its Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at treating cancer-related anorexia and weight loss. The study will assess 40 patients, using a 3:1 ratio for ART27.13 versus placebo over 12 weeks. Following positive safety outcomes in Phase 1b, a dose of 650 micrograms will be administered. About 18 clinical sites across five countries will participate. ART27.13 targets cannabinoid receptors and has shown potential for increasing appetite without adverse central nervous system effects. The global market for addressing anorexia in cancer patients is estimated over $2 billion. The company hopes to complete patient enrollment by mid-2024.
Artelo Biosciences (Nasdaq: ARTL) reported significant developments for the fiscal year ending December 31, 2022, highlighting $17.5 million in cash and marketable securities available to support operations into the latter half of 2024. The CEO emphasized advances in their clinical trial for ART27.13, aimed at treating cancer-related anorexia, with enrollment completion of all cohorts and the next Phase 2a stage anticipated to start in April 2023. The company also noted a net loss of $10.1 million for the year and a strategic full pipeline development, including research on their lead fatty acid binding protein inhibitor.